Veerhealth Care Limited is proud to announce that the Company had received request from USFDA on 04/09/2024 about submission of required documentation against FDA Form 4003, which was being requested under Section 704 of the Federal Food, Drug and Cosmetic Act (FD&C Act) [21 USC 374(a)].Following the records request as above, Company had submitted all the required data to USFDA on 18/09/2024.Upon submission of the required documentation, USFDA has issued FDA Form 4003a Records Receipt Confirmation and has confirmed that there are no further requests at this time, and have closed their RRA assessment.The successful completion of RRA assessment by the USFDA, would enable Company to open up its business in the USA market.
Veerhealth Care Limited Press Release Dec 11 2024
Filed with BSE · · 1 page · English
Release
Veerhealth Care Limited on 6ix
Earlier from Veerhealth Care
- Veerhealth Care Limited Press Release Nov 26 2024
- Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Rights Issue Draft Letter Of Offer
- Veerhealth Care Limited Press Release Nov 14 2024
- Results-Financial Results For September 30, 2024
- Board Meeting Outcome for Outcome Of Board Meeting
Later from Veerhealth Care
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Veerhealth Care Limited Press Release Dec 12 2024
- Announcement Under Regulation 30 (LODR) - Introduction Of New Division In Hospital Care Segment
- Veerhealth Care Limited Press Release Dec 18 2024
- Veerhealth Care Limited Press Release Dec 19 2024
Follow Veerhealth Care into a list and get an email when it puts out news.
Follow Veerhealth Care